Zuellig Pharma opens a 3,800-square-meter clinical trial center in South Korea to boost global research logistics and treatment access.

GEN Pharmaceuticals reports SUL-238, a promising Alzheimer’s and Parkinson’s drug, showed safety and brain delivery in early trial.

Inhaled nitrous oxide at 50% may rapidly ease treatment-resistant depression, with effects in 24 hours, but benefits fade without continued use.

Scientists developed a new bioreactor method to mass-produce lung organoids for personalized disease research and drug testing.

AIIMS released results for the 2026 super-specialty entrance test, determining eligibility for top medical programs.

FDA approves Axogen’s nerve graft for peripheral nerve repair, pending confirmatory trials.

Innovent and Takeda closed a $11.4B deal for three cancer drugs, with Takeda leading U.S. development of one and sharing profits 40/60 in the U.S.

On Nov. 29, 2025, Eli Lilly, Novo Nordisk, AbbVie, Pfizer, and Regeneron were highlighted as top pharma stocks due to strong performance and promising drug pipelines.

Sun Pharma launches ILUMYA for psoriasis in India, offering new treatment despite minor stock dip.

Cannabis use linked to reduced alcohol intake and liver disease risk in frequent users, per two 2025 studies.